Global Blood Therapeutics said to draw takeover interest, reveals Bloomberg - Part 2

It would appear Johnson & Johnson was also circling US-listed Global Blood Therapeutics, which two weeks ago agreed a deal to sell itself to pharmaceutical giant Pfizer for $5.4 billion.

You need to register and sign in to read this content.